Suppr超能文献

术前化疗期间的肿瘤进展预示着无法完成结直肠癌肝转移的两阶段肝切除术:一项对130例患者的意大利多中心分析结果

Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients.

作者信息

Giuliante Felice, Ardito Francesco, Ferrero Alessandro, Aldrighetti Luca, Ercolani Giorgio, Grande Gennaro, Ratti Francesca, Giovannini Ivo, Federico Bruno, Pinna Antonio D, Capussotti Lorenzo, Nuzzo Gennaro

机构信息

Hepatobiliary Surgery Unit, A. Gemelli Hospital, Università Cattolica del Sacro Cuore, Rome, Italy.

Hepatobiliary Surgery Unit, A. Gemelli Hospital, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

J Am Coll Surg. 2014 Aug;219(2):285-94. doi: 10.1016/j.jamcollsurg.2014.01.063. Epub 2014 Apr 13.

Abstract

BACKGROUND

We aimed to evaluate the feasibility and long-term results of 2-stage hepatectomy (TSH) in patients with bilobar colorectal liver metastases (CRLM).

STUDY DESIGN

We performed a retrospective multicenter study including 4 Italian hepatobiliary surgery units. One hundred thirty patients were selected for TSH between 2002 and 2011. The primary endpoint was feasibility of TSH and analysis of factors associated with failure to complete the procedure. The secondary endpoint was the long-term survival analysis.

RESULTS

Patients presented with synchronous CRLM in 80.8% of cases, with a mean number of 8.3 CRLM and with concomitant extrahepatic disease in 20.0% of cases. The rate of failure to complete TSH was 21.5% and tumor progression was the most frequent reason for failure (18.5% of cases). Primary tumor characteristics, type, number, and distribution of CRLM were not associated with significantly different risks of disease progression. Multivariable logistic regression analysis showed that tumor progression during prehepatectomy chemotherapy was the only independent risk factor for failure to complete TSH. The 5- and 10-year overall survival rates for patients who completed TSH were 32.1% and 24.1%, respectively, with a median survival of 43 months. Duration of prehepatectomy chemotherapy ≥6 cycles was found to be the only independent predictor of overall and disease-free survival.

CONCLUSIONS

This study showed that selection of patients by response to prehepatectomy chemotherapy may be extremely important before planning TSH because tumor progression while receiving prehepatectomy chemotherapy was associated with significantly higher risk of failure to complete the second stage. For patients who completed the TSH strategy, long-term outcomes can be achieved with results similar to those observed after single-stage hepatectomy.

摘要

背景

我们旨在评估两阶段肝切除术(TSH)在双叶结直肠癌肝转移(CRLM)患者中的可行性和长期结果。

研究设计

我们进行了一项回顾性多中心研究,纳入了4个意大利肝胆外科单位。2002年至2011年间,130例患者被选择进行TSH。主要终点是TSH的可行性以及与手术未完成相关因素的分析。次要终点是长期生存分析。

结果

80.8%的病例为同时性CRLM,平均CRLM数量为8.3个,20.0%的病例伴有肝外疾病。TSH未完成率为21.5%,肿瘤进展是最常见的失败原因(18.5%的病例)。原发性肿瘤特征、CRLM的类型、数量和分布与疾病进展风险无显著差异。多变量逻辑回归分析显示,肝切除术前化疗期间的肿瘤进展是TSH未完成的唯一独立危险因素。完成TSH的患者5年和10年总生存率分别为32.1%和24.1%,中位生存期为43个月。肝切除术前化疗持续时间≥6个周期是总生存和无病生存的唯一独立预测因素。

结论

本研究表明,在计划TSH之前,根据肝切除术前化疗反应选择患者可能极其重要,因为在接受肝切除术前化疗时肿瘤进展与完成第二阶段手术失败的风险显著更高相关。对于完成TSH策略的患者,可以实现长期结果,其结果与一期肝切除术后观察到的结果相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验